Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Teva Pharmaceutical Industries Limited
  6. News
  7. Summary
    TEVA   US8816242098

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

(TEVA)
  Report
Real-time Estimate Cboe BZX  -  11:25:34 2023-03-28 am EDT
8.805 USD   +0.86%
11:16aTeva's Digital Health Collaboration with Rimidi Expands to Include Respiratory Monitoring Program Integration with a Large U.S. Health System
AQ
03/27Teva's Digital Health Collaboration with Rimidi Expands to Include Respiratory Monitoring Program Integration with a Large U.S. Health System
BU
03/27Teva Pharmaceutical Industries Ltd. Collaboration with Rimidi Expands to Include Respiratory Monitoring Program Integration with A Large U.S. Health System
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Teva Pharmaceutical Industries Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022

02/08/2023 | 07:00am EDT
share with twitter
share with LinkedIn
share with facebook

Teva Pharmaceutical Industries Limited reported earnings results for the fourth quarter and full year ended December 31, 2022. For the fourth quarter, the company reported sales was USD 3,884 million compared to USD 4,100 million a year ago. Net loss was USD 1,221 million compared to USD 159 million a year ago. Basic loss per share from continuing operations was USD 1.1 compared to USD 0.14 a year ago. Diluted loss per share from continuing operations was USD 1.1 compared to USD 0.14 a year ago.
For the full year, sales was USD 14,925 million compared to USD 15,878 million a year ago. Net loss was USD 2,353 million compared to net income of USD 417 million a year ago. Basic loss per share from continuing operations was USD 2.12 compared to basic earnings per share from continuing operations of USD 0.38 a year ago. Diluted loss per share from continuing operations was USD 2.12 compared to diluted earnings per share from continuing operations of USD 0.38 a year ago.


© S&P Capital IQ 2023
All news about TEVA PHARMACEUTICAL INDUSTRIES LIMITED
11:16aTeva's Digital Health Collaboration with Rimidi Expands to Include Respiratory Monitori..
AQ
03/27Teva's Digital Health Collaboration with Rimidi Expands to Include Respiratory Monitori..
BU
03/27Teva Pharmaceutical Industries Ltd. Collaboration with Rimidi Expands to Include Respir..
CI
03/16ART Medical Ltd. Announces Partnership with Teva Israel to Bring Its Lifesaving Technol..
CI
03/14Transcript : Teva Pharmaceutical Industries Limited Presents at Barclays Glob..
CI
03/13Teva Announces Early Tender Results of its Debt Tender Offer, Increases to Tender Caps ..
BU
03/10Teva and Natco Announce Launch of additional strengths for the Generic Version of Revli..
AQ
03/09Teva Pharmaceutical Industries Ltd : Entry into a Material Definitive Agreement, Creation ..
AQ
03/09Teva Pharmaceuticals, Natco Pharma Launch Two Additional Strengths for Generic Version ..
MT
03/09Teva and Natco Announce Launch of additional strengths for the Generic Version of Revli..
BU
More news
Analyst Recommendations on TEVA PHARMACEUTICAL INDUSTRIES LIMITED
More recommendations
Financials (USD)
Sales 2023 14 969 M - -
Net income 2023 396 M - -
Net Debt 2023 17 444 M - -
P/E ratio 2023 25,0x
Yield 2023 -
Capitalization 9 698 M 9 698 M -
EV / Sales 2023 1,81x
EV / Sales 2024 1,65x
Nbr of Employees 34 565
Free-Float 90,5%
Chart TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Duration : Period :
Teva Pharmaceutical Industries Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Last Close Price 8,73 $
Average target price 10,11 $
Spread / Average Target 15,8%
EPS Revisions
Managers and Directors
Richard Francis President, Chief Executive Officer & Director
Eli Kalif Chief Financial Officer & Executive Vice President
Sol J. Barer Chairman
Eric A. Hughes Chief Medical Officer, Executive VP-Global R&D
Eric Drapé SVP-Technical Operations Steriles & Respiratory
Sector and Competitors
1st jan.Capi. (M$)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED-7.46%9 698
JOHNSON & JOHNSON-13.59%400 664
NOVO NORDISK A/S13.75%347 275
ELI LILLY AND COMPANY-8.54%301 775
ABBVIE INC.-2.52%277 923
MERCK & CO., INC.-3.62%271 452
MarketScreener: Created by Investors for Investors!
100% Free Registration
fermer